Current clinical trials of 17-AAG and 17-DMAG - Referral resource

被引：0
|
作者：
Ivy, PS [1 ]
Schoenfeldt, M
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] Emmes Corp, Rockville, MD USA
来源：
ONCOLOGY-NEW YORK | 2004年 / 18卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：610 / 610
页数：1
相关论文
共 50 条
  • [1] 17-DMAG (NSC 707545), a water-soluble geldanamycin analog, has superior in vitro and in vivo antitumor activity compared to the hsp90 inhibitor 17-AAG
    Smith, V
    Sausville, EA
    Camalier, RF
    Fiebig, HH
    Burger, AM
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 : S60 - S60
  • [2] Comparison of Inhibitory Effect of 17-DMAG Nanoparticles and Free 17-DMAG in HSP90 Gene Expression in Lung Cancer
    Mellatyar, Hassan
    Akbarzadeh, Abolfazl
    Rahmati, Mohammad
    Ghalhar, Masoud Gandomkar
    Etemadi, Ali
    Nejati-Koshki, Kazem
    Zarghami, Nosratallah
    Barkhordari, Amin
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (20) : 8693 - 8698
  • [3] 17-AAG: mechanisms of antitumour activity
    Konstantinopoulos, PA
    Papavassiliou, AG
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (12) : 1471 - 1474
  • [4] Effect of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on uveal melanoma cells
    Faingold, Dana
    Marshall, Jean-Claude
    Bakalian, Silvin
    Odashiro, Alexandre N.
    Godeiro, Katyanne D.
    Burnier, Miguel N., Jr.
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [5] MicroRNAs that chemosensitize the apoptotic effect of 17-AAG
    Hwang, Larn
    Treece, Tina
    Desai, Neil
    Trieu, Vuong
    [J]. CANCER RESEARCH, 2010, 70
  • [6] Tanespimycin (17-allylamino-17-demethoxy-geldanamycin; 17-AAG) in breast cancer
    Modi, S.
    Sugarman, S.
    Stopeck, A.
    Linden, H.
    Ma, W.
    Chandarlapaty, S.
    Solit, D.
    Norton, L.
    Rosen, N.
    Kersey, K.
    Johnson, R.
    Hannah, A.
    Hudis, C.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 18 - 18
  • [7] Comparison of Inhibitory Effects of 17-AAG Nanoparticles and Free 17-AAG on HSP90 Gene Expression in Breast Cancer
    Ghalhar, Masoud Gandomkar
    Akbarzadeh, Abolfazl
    Rahmati, Mohammad
    Mellatyar, Hassan
    Dariushnejad, Hassan
    Zarghami, Nosratallah
    Barkhordari, Amin
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (17) : 7113 - 7118
  • [8] Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) administered twice weekly
    Murgo, A. J.
    Kummar, S.
    Gardner, E. R.
    Figg, W.
    Chen, X.
    Yancey, M.
    Ivy, P.
    Conley, B.
    Doroshow, J. H.
    Gutierrez, M. E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance
    Glaze, ER
    Lambert, AL
    Smith, AC
    Page, JG
    Johnson, WD
    McCormick, DL
    Brown, AP
    Levine, BS
    Covey, JM
    Egorin, MJ
    Eiseman, JL
    Holleran, JL
    Sausville, EA
    Tomaszewski, JE
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (06) : 637 - 647
  • [10] In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non-water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines
    Ghadban, Tarik
    Jessen, Andre
    Reeh, Matthias
    Dibbern, Judith L.
    Mahner, Sven
    Mueller, Volkmar
    Wellner, Ulrich F.
    Gungor, Cenap
    Izbicki, Jakob R.
    Vashist, Yogesh K.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 38 (04) : 1296 - 1302
12345